Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Networking & Security • Semiconductors, Circuits & Optics
8 pending office actions • 4 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Tokyo University of Science Foundation currently has 8 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio is spread across 8 distinct examiners, indicating that each examiner is currently managing exactly one action. These matters are distributed among 4 distinct art units, which shows some diversity in the specific technical classifications of the foundation's patent applications.
SHIZHI QIAN is identified as the busiest examiner with 1 pending action. This distribution suggests that the foundation's prosecution efforts are not concentrated under a single individual but are instead handled by a broad group of 8 distinct examiners. The presence of 4 distinct art units within the biotechnology sector reflects a range of specialized research areas being pursued by the foundation. This variety requires the foundation to navigate different examination styles and unit-specific practices at the USPTO. With 8 pending office actions, the foundation's patent strategy involves a wide array of individual interactions, even with a relatively small number of pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 2 (25%) |
| Multi-statute (no §101) | 5 (62%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| QIAN, SHIZHI | 1 | 61.8% | +47.9% |
| CUMAR, NATHAN | 1 | 78.8% | +14.4% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| WAHEED, NAZRA NUR | 1 | 84.6% | +10.7% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.2% |
| SAIFUDDIN, AHMED | 1 | 82.2% | +23.3% |
| LAU, JONATHAN S | 1 | 63.7% | -17.3% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683707 | TRANSMISSION DEVICE, COMMUNICATION SYSTEM, TRANSMISSION METHOD, AND PROGRAM | SAIFUDDIN, AHMED | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19105926 | ALL-SOLID-STATE POTASSIUM ION SELECTIVE ELECTRODE, AND METHOD FOR PRODUCING SAME | QIAN, SHIZHI | — |
| 18702584 | RUBBER PRODUCT, TEST JIG AND TEST DEVICE FOR SEALING MEMBER, AND LEAKAGE DETECTION MEMBER | CUMAR, NATHAN | — |
| 18708827 | ANTI-SARS-COV-2 DRUG | WARD, PAUL V | — |
| 18844991 | RADIO WAVE REFLECTOR | WAHEED, NAZRA NUR | — |
| 18289934 | Glycosylated Neuropeptide Derivative, Pharmaceutical Composition, Intranasal/Nasal Drop Formulation, and Use of Pharmaceutical Composition | ALLEN, MARIANNE P | — |
| 18566013 | CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME | LAU, JONATHAN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19105926 | ALL-SOLID-STATE POTASSIUM ION SELECTIVE ELECTRODE, AND METHOD FOR PRODUCING SAME | QIAN, SHIZHI | — |
| 18702584 | RUBBER PRODUCT, TEST JIG AND TEST DEVICE FOR SEALING MEMBER, AND LEAKAGE DETECTION MEMBER | CUMAR, NATHAN | — |
| 18844991 | RADIO WAVE REFLECTOR | WAHEED, NAZRA NUR | — |
| 18289934 | Glycosylated Neuropeptide Derivative, Pharmaceutical Composition, Intranasal/Nasal Drop Formulation, and Use of Pharmaceutical Composition | ALLEN, MARIANNE P | — |
| 18683707 | TRANSMISSION DEVICE, COMMUNICATION SYSTEM, TRANSMISSION METHOD, AND PROGRAM | SAIFUDDIN, AHMED | — |
| 18264396 | MESENCHYMAL STEM CELLS AND ADIPOCYTES FOR PREPARING MITOKINE MIXTURE, AND THERAPEUTIC OR PROPHYLACTIC DRUG | NGUYEN, NGHI V | — |
| Art Unit | Apps |
|---|---|
| 2844 | 1 |
| 2475 | 1 |
| 1693 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19105926 | ALL-SOLID-STATE POTASSIUM ION SELECTIVE ELECTRODE, AND METHOD FOR PRODUCING SAME | QIAN, SHIZHI | — | §103§112 | Non-Final OA | — | Pending | Feb 24, 2025 |
| 18702584 | RUBBER PRODUCT, TEST JIG AND TEST DEVICE FOR SEALING MEMBER, AND LEAKAGE DETECTION MEMBER | CUMAR, NATHAN | — | §102§103 | Non-Final OA | — | Pending | Dec 30, 2024 |
| 18708827 | ANTI-SARS-COV-2 DRUG | WARD, PAUL V | — | §102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18844991 | RADIO WAVE REFLECTOR | WAHEED, NAZRA NUR | 2844 | §103§112 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18289934 | Glycosylated Neuropeptide Derivative, Pharmaceutical Composition, Intranasal/Nasal Drop Formulation, and Use of Pharmaceutical Composition | ALLEN, MARIANNE P | — | §101§103§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18683707 | TRANSMISSION DEVICE, COMMUNICATION SYSTEM, TRANSMISSION METHOD, AND PROGRAM | SAIFUDDIN, AHMED | 2475 | §103 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18566013 | CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME | LAU, JONATHAN S | 1693 | §103§112 | Final Rejection | — | Pending | Nov 30, 2023 |
| 18264396 | MESENCHYMAL STEM CELLS AND ADIPOCYTES FOR PREPARING MITOKINE MIXTURE, AND THERAPEUTIC OR PROPHYLACTIC DRUG | NGUYEN, NGHI V | 1653 | §103 | Final Rejection | — | Pending | Aug 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial